title: FXR: Big fish or small fry for drug-induced liver injury?
abstract: By integrating network analysis and molecular modeling, a "system pharmacology" approach identified FXR as a potential off-target protein mediating non-steroidal anti-inflammatory drugs (NSAID)-induced liver injury. In vitro assays showed that NSAID are potent FXR antagonists that inhibit FXR transcriptional activity. Given the role of FXR in bile acid homeostasis, liver inflammation and cell proliferation, the data suggest that FXR antagonism could mediate, at least in part, NSAID-induced liver injury.
authors.affiliation: Medicen Paris Region, 3-5, impasse Reille, 75014 Paris, France. Electronic address: fballet@medicen.org.
authors.forename: François
authors.initials: F
authors.lastname: Ballet
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology*; D006801:Humans; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors*; D049490:Systems Biology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018160:Receptors, Cytoplasmic and Nuclear